Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer

被引：0
|
作者：
Kenji Nakahama
Motohiro Izumi
Naoki Yoshimoto
Mitsuru Fukui
Akira Sugimoto
Hiroaki Nagamine
Koichi Ogawa
Kenji Sawa
Yoko Tani
Hiroyasu Kaneda
Shigeki Mitsuoka
Tetsuya Watanabe
Kazuhisa Asai
Tomoya Kawaguchi
机构：
[1] Osaka Metropolitan University,Department of Respiratory Medicine, Graduate School of Medicine
[2] Bell Land General Hospital,Department of Pulmonary Medicine
[3] Ishikiriseiki Hospital,Department of Pulmonary Medicine
[4] Osaka Metropolitan University,Department of Laboratory of Statistics, Graduate School of Medicine
[5] Osaka Metropolitan University,Department of Clinical Oncology, Graduate School of Medicine
来源：
Cancer Chemotherapy and Pharmacology | 2023年 / 92卷
关键词：
Immunotherapy; Krebs von den Lungen-6; Monotherapy; Predictor of poor survival; Programmed death-ligand 1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：381 / 390
页数：9
相关论文
共 50 条
  • [1] Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer
    Nakahama, Kenji
    Izumi, Motohiro
    Yoshimoto, Naoki
    Fukui, Mitsuru
    Sugimoto, Akira
    Nagamine, Hiroaki
    Ogawa, Koichi
    Sawa, Kenji
    Tani, Yoko
    Kaneda, Hiroyasu
    Mitsuoka, Shigeki
    Watanabe, Tetsuya
    Asai, Kazuhisa
    Kawaguchi, Tomoya
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 92 (05) : 381 - 390
  • [2] Vimentin expression correlates with immune-checkpoint inhibitor efficacy in non-small cell lung cancer
    Nakahama, Kenji
    Izumi, Motohiro
    Yoshimoto, Naoki
    Fukui, Mitsuru
    Sugimoto, Akira
    Nagamine, Hiroaki
    Ogawa, Koichi
    Sawa, Kenji
    Tani, Yoko
    Kaneda, Hiroyasu
    Mitsuoka, Shigeki
    Watanabe, Tetsuya
    Asai, Kazuhisa
    Kawaguchi, Tomoya
    CANCER, 2023, 129 (15) : 2297 - 2307
  • [3] Salvage extended surgery after immune-checkpoint inhibitor treatment for advanced non-small cell lung cancer
    Goto, Eisuke
    Hattori, Aritoshi
    Fukui, Mariko
    Matsunaga, Takeshi
    Takamochi, Kazuya
    Suzuki, Kenji
    SURGERY TODAY, 2024, 54 (08) : 917 - 926
  • [4] Patterns of response and progression with immune-checkpoint inhibitor combinations in advanced non-small cell lung cancer
    Brown, Lauren
    Ahn, Julie
    Gee, Harriet
    Nagrial, Adnan
    Hau, Eric
    Da Silva, Ines Pires
    RESPIROLOGY, 2023, 28 : 18 - 19
  • [5] Febrile Neutropenia in a Patient with Non-Small Cell Lung Cancer Treated with the Immune-Checkpoint Inhibitor Nivolumab
    Hisamatsu, Yasushi
    Morinaga, Ryotaro
    Watanabe, Erina
    Ohtani, Satoshi
    Shirao, Kuniaki
    AMERICAN JOURNAL OF CASE REPORTS, 2020, 21
  • [6] Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer
    Rossi, Emanuela
    Sgambato, Assunta
    De Chiara, Giovanni
    Casaluce, Francesca
    Losanno, Tania
    Sacco, Paola Claudia
    Santabarbara, Giuseppe
    Gridelli, Cesare
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (03) : 419 - 428
  • [7] Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology
    Manglaviti, Sara
    Brambilla, Marta
    Signorelli, Diego
    Ferrara, Roberto
    Lo Russo, Giuseppe
    Proto, Claudia
    Galli, Giulia
    De Toma, Alessandro
    Occhipinti, Mario
    Viscardi, Giuseppe
    Beninato, Teresa
    Zattarin, Emma
    Bini, Marta
    Lobefaro, Riccardo
    Massa, Giacomo
    Bottiglieri, Achille
    Apollonio, Giulia
    Sottotetti, Elisa
    Di Mauro, Rosa Maria
    Trevisan, Benedetta
    Ganzinelli, Monica
    Fabbri, Alessandra
    de Braud, Filippo G. M.
    Garassino, Marina Chiara
    Prelaj, Arsela
    CLINICAL LUNG CANCER, 2022, 23 (01) : E17 - E28
  • [8] Bringing immune-checkpoint inhibitors earlier in the management of non-small cell lung cancer
    Borgeaud, Maxime
    Friedlaender, Alex
    Addeo, Alfredo
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (11) : 2353 - 2358
  • [9] Clinical and laboratory predictors of immune checkpoint inhibitor efficacy in non-small cell lung cancer
    Christopoulos, P.
    Kohlhaeufl, J.
    Bozorgmehr, F.
    Kuon, J.
    Schneider, M.
    Neumann, O.
    Liersch, S.
    Heussel, C.
    Winter, H.
    Herth, F.
    Rieken, S.
    Muley, T.
    Meister, M.
    Bischoff, H.
    Lasitschka, F.
    Stenzinger, A.
    Thomas, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] Modifiable biomarkers of response to immune checkpoint inhibitor treatment in non-small cell lung cancer
    Spakowicz, D.
    Williams, N.
    Bibi, A.
    Hoyd, R.
    Wheeler, C. E.
    Suman, S.
    Amann, J.
    Okimoto, T.
    Grogan, M.
    Vibhakar, P.
    Owen, D.
    Carbone, D. P.
    Presley, C.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S345 - S346
12345